NEWSROOM

Formation Minerals, Inc. Provides Fiscal Year End Corporate Update

Formation Minerals, Inc. Provides Fiscal Year End Corporate Update

Jacksboro, Texas, August 14, 2024 – Formation Minerals, Inc. (OTCQB: FOMI) (“Formation” or the “Company”), a growing oil and gas company with a focus on the acquisition and management of oil and gas minerals and royalties, today provided its fiscal year-end stockholder update. To our valued friends and stockholders, We hope that this letter finds you well and enjoying the summer. We at Formation continue to execute our strategy and are pleased to provide a corporate update in connection with...

read more
Metatron Announces QuantumBeam – A Revolution in AI-Controlled Energy Transmission

Metatron Announces QuantumBeam – A Revolution in AI-Controlled Energy Transmission

Dover, DE, August 13th, 2024 – Metatron Apps Inc (OTC: MRNJ) ($MRNJ), leading developer of over 1000 mobile apps proudly introduces QuantumBeam, a groundbreaking service that harnesses AI-designed and controlled cloud technology to deliver continuous energy transmission through quantum entanglement. This cutting-edge platform offers unparalleled benefits such as enhanced vitality, stress reduction, and EMF mitigation, backed by rigorous scientific studies demonstrating its effectiveness....

read more
Sono-Tek Announces Additional $2.95 Million Order from Specialty Clean Energy Customer

Sono-Tek Announces Additional $2.95 Million Order from Specialty Clean Energy Customer

4 System Order Expected to be Shipped in Fiscal 2026 Company Experiencing Strong Demand from Clean Energy Sector MILTON, NY, August 13, 2024 — Sono-Tek Corporation (Nasdaq: SOTK), a leading developer and manufacturer of ultrasonic coating systems, is pleased to announce the receipt of an additional $2.95 million order from an existing clean energy customer. This new order, identical in value and scope to a recent record-breaking order from the same customer, reinforces Sono-Tek’s position as a...

read more
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp.  (Nasdaq: OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were monitored for antibody-mediated rejection (AMR) using its proprietary VitaGraft™ Kidney diagnostic test. Patients were tested before, during...

read more
BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving an impressive 56.5% sequential revenue increase compared to Q1 2024 Achieves second consecutive quarter of positive net income with $6.3 million Generated Adjusted Q2 2024 EBITDA of $10.0 million Financial Results Conference Call and Webcast on Monday, August 12, 2024, at 4:30 pm EDT POMPANO...

read more
SKYX Reports Record Second Quarter Sales of $21.4 Million Compared to $15.0 Million for Second Quarter 2023 as it Continues to Grow its Market Penetration in the U.S and Canada of its Advanced and Smart Platform Products

SKYX Reports Record Second Quarter Sales of $21.4 Million Compared to $15.0 Million for Second Quarter 2023 as it Continues to Grow its Market Penetration in the U.S and Canada of its Advanced and Smart Platform Products

MIAMI, FL, August 12, 2024 – SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 97 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today reported its financial and operational results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Achievements Generated...

read more
AB INTL GROUP Reports of Financial Results for period ending May 31, 2024 and achieved Net Profitability

AB INTL GROUP Reports of Financial Results for period ending May 31, 2024 and achieved Net Profitability

NEW YORK, August 12, 2024 -- AB International Group Corp. (OTC: ABQQ), an intellectual property (IP) and movie investment and licensing firm, announces its financial results for the period ended May 31, 2024. The financial results have been filed in a 10-Q with the U.S. Securities and Exchange Commission (the "SEC"). Key Financial Highlights: Revenues for the three months ended May 31, 2024, increased 22% to $698,311, as compared to $573,389 for the three months ended May 31, 2023. Net income...

read more
StemSation International Provides Corporate Updates

StemSation International Provides Corporate Updates

StemSation International is providing updates on corporate planning and direction as they execute on an expanded business model Plantation, Florida, August 12, 2024 – StemSation International (OTC: STSN), a South-Florida based company that has licensed technology for the production and distribution of flavored, canned oxygen products is announcing new business initiatives for the upcoming months. "We announced last year that we had streamlined our current business and would be seeking further...

read more
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Top Line Data Expected Year-End 2024 Pittsburgh, August 12, 2024 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” “we” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients. Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects...

read more
ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

Melanocortin receptors on neurons in the brain control feeding and weight loss Patented peptide molecules delivered orally as a pill can control feeding disorders and weight loss NEW YORK, NY, August 09, 2024 - ANEW MEDICAL, INC. (NASDAQ: WENA) has announced that, as a result of its worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona, it plans to pursue the development of therapeutics using novel proprietary peptides that selectively bind and activate...

read more

Contact Us

PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850